Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Gross Profit (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Gross Profit data on record, last reported at $9.5 million in Q3 2025.

  • For Q3 2025, Gross Profit fell 0.59% year-over-year to $9.5 million; the TTM value through Sep 2025 reached $35.6 million, up 117.24%, while the annual FY2024 figure was $29.1 million, 31.6% down from the prior year.
  • Gross Profit reached $9.5 million in Q3 2025 per PLX's latest filing, down from $9.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $28.9 million in Q2 2023 and bottomed at $1.1 million in Q1 2024.
  • Average Gross Profit over 5 years is $7.5 million, with a median of $6.5 million recorded in 2023.
  • The widest YoY moves for Gross Profit: up 779.26% in 2024, down 86.11% in 2024.
  • A 5-year view of Gross Profit shows it stood at $5.4 million in 2021, then rose by 15.16% to $6.2 million in 2022, then crashed by 73.79% to $1.6 million in 2023, then soared by 779.26% to $14.3 million in 2024, then tumbled by 33.53% to $9.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $9.5 million in Q3 2025, $9.8 million in Q2 2025, and $1.9 million in Q1 2025.